Biomarker Discovery Platform

About Intus Biosciences

Intus Biosciences is an early-stage biotech leveraging a proprietary AI-powered platform, Titan-1™, to analyze the human microbiome at an unprecedented strain-level resolution. The company's technology is positioned to enable breakthroughs in non-invasive diagnostics, particularly for early cancer detection and chronic diseases, by transforming complex microbiome data into actionable health intelligence. While currently private and likely pre-revenue, Intus Bio is actively engaging in research collaborations and has launched a direct-to-consumer gut health test, GutID™, as an initial commercial application. Its strategy involves validating its platform through partnerships and publications to ultimately drive adoption in clinical research and precision medicine.

About BiomeSense

BiomeSense is a microbiome data infrastructure company building a proprietary platform to generate and analyze continuous, high-resolution gut microbiome data. The company's technology integrates the GutLab system for at-home sample collection and the MetaBiome AI platform for advanced time-series analysis, targeting the limitations of current costly and sparse microbiome sampling. BiomeSense partners with research institutions and biopharma companies to support exploratory research, biomarker discovery, and product development in the microbiome space, positioning the gut microbiome as a next frontier in precision medicine.

Therapeutic Areas